Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Clinical and statistical considerations in personalized medicine / / edited by Claudio Carini, Pfizer, Cambridge, Massachusetts, USA, Sandeep M. Menon, Pfizer, Cambridge, Massachusetts, USA, Mark Chang, AMAG Pharmaceuticals, Incorporated Waltham, Massach
| Clinical and statistical considerations in personalized medicine / / edited by Claudio Carini, Pfizer, Cambridge, Massachusetts, USA, Sandeep M. Menon, Pfizer, Cambridge, Massachusetts, USA, Mark Chang, AMAG Pharmaceuticals, Incorporated Waltham, Massach |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , [2014] |
| Descrizione fisica | 1 online resource (368 p.) |
| Disciplina |
615.7072/7
615.70727 |
| Collana | Chapman and Hall/CRC Biostatistics Series |
| Soggetto topico |
Pharmacogenetics - Mathematical models
Pharmacogenetics - Statistical methods Pharmacogenomics - Mathematical models Pharmacogenomics - Statistical methods |
| ISBN |
0-429-16933-7
1-4665-9387-3 |
| Classificazione | MAT029000MED045000MED071000 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Contents; Preface; Editors; Contributors; Chapter 1: Biomarkers for Drug Development: The Time Is Now!; Chapter 2: RNAi Screens: Triumphs and Tribulations; Chapter 3: Current Advances in Epigenetics; Chapter 4: Biomarkers and Precision Medicine: The Case of Rare Diseases; Chapter 5: Biomarker-Informed Adaptive Design; Chapter 6: Fitting the Dose: Adaptive Staggered Dose Design; Chapter 7: Evidence-Based Adaptive Statistical Decision and Design Strategies for; Chapter 8: Biomarker Identification in Clinical Trials; Chapter 9: Multiplicity in Pharmacogenomics
Chapter 10: Patient-Reported Outcomes in Personalized MedicineChapter 11: Regulatory Issues in Use of Biomarkers in Drug Development; Back Cover |
| Record Nr. | UNINA-9910789244103321 |
| Boca Raton : , : CRC Press, , [2014] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical and statistical considerations in personalized medicine / / edited by Claudio Carini, Pfizer, Cambridge, Massachusetts, USA, Sandeep M. Menon, Pfizer, Cambridge, Massachusetts, USA, Mark Chang, AMAG Pharmaceuticals, Incorporated Waltham, Massach
| Clinical and statistical considerations in personalized medicine / / edited by Claudio Carini, Pfizer, Cambridge, Massachusetts, USA, Sandeep M. Menon, Pfizer, Cambridge, Massachusetts, USA, Mark Chang, AMAG Pharmaceuticals, Incorporated Waltham, Massach |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , [2014] |
| Descrizione fisica | 1 online resource (368 p.) |
| Disciplina |
615.7072/7
615.70727 |
| Collana | Chapman and Hall/CRC Biostatistics Series |
| Soggetto topico |
Pharmacogenetics - Mathematical models
Pharmacogenetics - Statistical methods Pharmacogenomics - Mathematical models Pharmacogenomics - Statistical methods |
| ISBN |
0-429-16933-7
1-4665-9387-3 |
| Classificazione | MAT029000MED045000MED071000 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Contents; Preface; Editors; Contributors; Chapter 1: Biomarkers for Drug Development: The Time Is Now!; Chapter 2: RNAi Screens: Triumphs and Tribulations; Chapter 3: Current Advances in Epigenetics; Chapter 4: Biomarkers and Precision Medicine: The Case of Rare Diseases; Chapter 5: Biomarker-Informed Adaptive Design; Chapter 6: Fitting the Dose: Adaptive Staggered Dose Design; Chapter 7: Evidence-Based Adaptive Statistical Decision and Design Strategies for; Chapter 8: Biomarker Identification in Clinical Trials; Chapter 9: Multiplicity in Pharmacogenomics
Chapter 10: Patient-Reported Outcomes in Personalized MedicineChapter 11: Regulatory Issues in Use of Biomarkers in Drug Development; Back Cover |
| Record Nr. | UNINA-9910806250903321 |
| Boca Raton : , : CRC Press, , [2014] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Policy Options Evaluation Tool for Managed Lanes (POET-ML) users guide and methodology description [[electronic resource] ] : Federal Highway Administration HOV lane performance / / [Andrew Smith, Claudia Bilotto, Mark Chang]
| Policy Options Evaluation Tool for Managed Lanes (POET-ML) users guide and methodology description [[electronic resource] ] : Federal Highway Administration HOV lane performance / / [Andrew Smith, Claudia Bilotto, Mark Chang] |
| Autore | Smith Andrew |
| Pubbl/distr/stampa | Washington D.C. : , : U.S. Dept. of Transportation, Federal Highway Administration, , 2008 |
| Descrizione fisica | 1 online resource (26 pages) : color illustrations |
| Altri autori (Persone) |
BilottoClaudia
ChangMark |
| Soggetto topico |
Managed lanes (Traffic engineering) - United States - Planning
High occupancy vehicle lanes - United States - Planning Toll roads - United States - Planning |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Policy Options Evaluation Tool for Managed Lanes |
| Record Nr. | UNINA-9910704907903321 |
Smith Andrew
|
||
| Washington D.C. : , : U.S. Dept. of Transportation, Federal Highway Administration, , 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||